BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-leqembi-iqlik-pdufa-aug2026@catalyst-calendar.local
DTSTAMP:20260720T200547Z
DTSTART:20260824T130000Z
DTEND:20260824T133000Z
SUMMARY:Leqembi IQLIK皮下注射起始剂量FDA PDUFA窗口
DESCRIPTION:Eisai和Biogen宣布FDA将Leqembi IQLIK作为早期阿尔茨海默病起始剂量的sBLA审评延长三个月，新的PDUFA日期为2026年8月24日；该事件可能影响抗淀粉样蛋白疗法商业化路径和神经退行性疾病板块预期。\\nImpact score: 72\\nExpected: 关注FDA是否批准皮下注射起始剂量，从而降低输注负担并扩大Leqembi可及性。\\nAffected: BIIB(subject\, mixed\, score 78)\; 4523.T(subject\, mixed\, score 80)\; LLY(peer\, mixed\, score 58)\; IBB(etf\, mixed\, score 54)\; XBI(etf\, mixed\, score 52)\\nSources: Eisai official release: https://www.eisai.com/news/2026/news202625.html\\nBiogen investor release: https://investors.biogen.com/news-releases/news-release-details/update-fda-priority-review-leqembir-iqliktm-lecanemab-irmb\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-leqembi-iqlik-pdufa-aug2026
CATEGORIES:fda\,US\,FDA\,PDUFA\,Alzheimer\,Leqembi
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Leqembi IQLIK皮下注射起始剂量FDA PDUFA窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Leqembi IQLIK皮下注射起始剂量FDA PDUFA窗口
END:VALARM
END:VEVENT
END:VCALENDAR